High-cost-per-dose large molecules can make a big impact on cell and gene therapy supply chain management.
Matthew Lakelin, PhD
Advertisement
Articles by Matthew Lakelin, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on BioPharm International
1
How Enzymatic Platforms May Change the Therapeutic RNA Supply Chain
2
How Is AI Transforming Biomanufacturing and Biopharma Workforce Training?
3
BioPharma By the Numbers: Bioprocess Hiring Creating Capacity Constraints
4
Q&A: Strategies for Supply Chain Resilience and Next-Generation Process Optimization
5
